Avians Biomedicals Soars 99.5% on Listing Day, Delivers Windfall Gains to IPO Investors
Suspense Crime, Digital Desk : Shares of biotech-sector company Avians Biomedicals made a spectacular debut on the stock market on Thursday, rewarding IPO investors with substantial gains on the very first day of trading.
The company's shares were issued at ₹208 apiece under its initial public offering (IPO). On listing, the stock debuted at ₹395.20 on the NSE SME platform, representing a premium of 90 per cent over the issue price. Strong buying interest continued after listing, pushing the stock to its upper circuit limit of ₹414.95 within a short period.
As a result, IPO investors gained ₹206.95 per share, translating into a return of nearly 99.5 per cent on their investment on the first day of trading.
Avians Biomedicals' ₹30.24-crore IPO was open for subscription from June 18 to June 22 and received an overwhelming response from investors. The issue was subscribed 385.32 times overall.
The Qualified Institutional Buyers (QIB) portion was subscribed 196.77 times, while the Non-Institutional Investors (NII) segment attracted subscriptions of 597.23 times. The retail investor category was subscribed 401.36 times, reflecting strong demand across all investor classes.
Under the IPO, the company issued a total of 1,453,800 equity shares with a face value of ₹10 each. According to the company, the funds raised through the issue will be utilised to meet working capital requirements and for general corporate purposes.
According to the financial information disclosed in the Draft Red Herring Prospectus (DRHP) filed with market regulator SEBI, the company's financial performance has shown consistent improvement in recent years.
Avians Biomedicals reported a net profit of ₹2.14 crore in the financial year 2023-24. This increased significantly to ₹7.23 crore in FY 2024-25. During the period from April 2025 to January 31, 2026, the company had already recorded a net profit of ₹5.74 crore.
The company's revenue also witnessed steady growth. Total revenue stood at ₹24.37 crore in FY 2023-24 and rose to ₹45.97 crore in FY 2024-25. Between April 2025 and January 31, 2026, the company generated revenue of ₹41.94 crore.
However, the company's debt levels also increased during the same period. Outstanding borrowings rose from ₹15.13 crore at the end of FY 2023-24 to ₹22.16 crore in FY 2024-25. By January 31, 2026, total debt had further increased to ₹26.73 crore.
At the same time, Avians Biomedicals strengthened its reserves and surplus position. The figure rose from ₹2.93 crore in FY 2023-24 to ₹18.75 crore in FY 2024-25 and further increased to ₹24.49 crore during the period ending January 31, 2026.
The company's EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortisation) also registered substantial growth. EBITDA stood at ₹4.08 crore in FY 2023-24 and climbed to ₹11.41 crore in FY 2024-25. For the period from April 2025 to January 31, 2026, EBITDA was reported at ₹10.34 crore.
The strong market debut reflects investor confidence in the company's growth prospects and financial performance, making Avians Biomedicals one of the standout SME IPO listings of the year.
